[go: up one dir, main page]

WO2004070347A3 - Screening for modulators of fat storage - Google Patents

Screening for modulators of fat storage Download PDF

Info

Publication number
WO2004070347A3
WO2004070347A3 PCT/GB2004/000413 GB2004000413W WO2004070347A3 WO 2004070347 A3 WO2004070347 A3 WO 2004070347A3 GB 2004000413 W GB2004000413 W GB 2004000413W WO 2004070347 A3 WO2004070347 A3 WO 2004070347A3
Authority
WO
WIPO (PCT)
Prior art keywords
screening
modulators
fat storage
compounds
fat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2004/000413
Other languages
French (fr)
Other versions
WO2004070347A2 (en
Inventor
Malcolm George Parker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial College Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd
Priority to EP04707568A priority Critical patent/EP1590674A2/en
Priority to CA002515347A priority patent/CA2515347A1/en
Priority to JP2006502228A priority patent/JP2006518591A/en
Priority to AU2004209335A priority patent/AU2004209335A1/en
Publication of WO2004070347A2 publication Critical patent/WO2004070347A2/en
Publication of WO2004070347A3 publication Critical patent/WO2004070347A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

This invention relates to screening methods for identifying compounds that are useful as modulators of fat storage. In particular, the invention provides methods of screening for compounds that modulate the function of receptor interacting protein 140 (RIP 140).
PCT/GB2004/000413 2003-02-03 2004-02-03 Screening for modulators of fat storage Ceased WO2004070347A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04707568A EP1590674A2 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage
CA002515347A CA2515347A1 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage
JP2006502228A JP2006518591A (en) 2003-02-03 2004-02-03 Storage fat modulator screening
AU2004209335A AU2004209335A1 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0302446.0A GB0302446D0 (en) 2003-02-03 2003-02-03 Screening for modulators of fat storage
GB0302446.0 2003-02-03

Publications (2)

Publication Number Publication Date
WO2004070347A2 WO2004070347A2 (en) 2004-08-19
WO2004070347A3 true WO2004070347A3 (en) 2004-12-16

Family

ID=9952335

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/000413 Ceased WO2004070347A2 (en) 2003-02-03 2004-02-03 Screening for modulators of fat storage

Country Status (6)

Country Link
EP (1) EP1590674A2 (en)
JP (1) JP2006518591A (en)
AU (1) AU2004209335A1 (en)
CA (1) CA2515347A1 (en)
GB (1) GB0302446D0 (en)
WO (1) WO2004070347A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691823B2 (en) * 2004-03-05 2010-04-06 University Of Massachusetts RIP140 regulation of glucose transport
JP2006090948A (en) * 2004-09-27 2006-04-06 Fuji Photo Film Co Ltd Screening method using biosensor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US20020004205A1 (en) * 2000-03-30 2002-01-10 Consler Thomas G. Method of investigating functional molecular interactions and reagents for use therein
EP1267171A1 (en) * 2001-06-14 2002-12-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cofactor-based screening method for nuclear receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4296608B2 (en) * 1997-08-27 2009-07-15 田辺三菱製薬株式会社 PPAR agonist and antagonist screening method
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
EP1241933B1 (en) * 1999-11-12 2008-10-01 Merck & Co., Inc. Melanocortin-3 receptor deficient cells, transgenic mice and methods of selecting compounds which regulate body weight

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6266622B1 (en) * 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US20020004205A1 (en) * 2000-03-30 2002-01-10 Consler Thomas G. Method of investigating functional molecular interactions and reagents for use therein
EP1267171A1 (en) * 2001-06-14 2002-12-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Cofactor-based screening method for nuclear receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PALOU A ET AL: "Obesity: Molecular bases of a multifactorial problem", EUROPEAN JOURNAL OF NUTRITION, vol. 39, no. 4, August 2000 (2000-08-01), pages 127 - 144, XP002279646, ISSN: 1436-6207 *
WHITE R ET AL: "The nuclear receptor co-repressor nrip1 (RIP140) is essential for female fertility", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 6, no. 12, December 2000 (2000-12-01), pages 1368 - 1374, XP002258567, ISSN: 1078-8956 *
YAMAUCHI TOSHIMASA ET AL: "The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 276, no. 44, 2 November 2001 (2001-11-02), pages 41245 - 41254, XP002279645, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
CA2515347A1 (en) 2004-08-19
AU2004209335A1 (en) 2004-08-19
JP2006518591A (en) 2006-08-17
GB0302446D0 (en) 2003-03-05
EP1590674A2 (en) 2005-11-02
WO2004070347A2 (en) 2004-08-19

Similar Documents

Publication Publication Date Title
WO2005014650A3 (en) Antibodies specific for sclerostin and methods for increasing bone mineralization
AU2002353403A1 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
IL174460A0 (en) Fully human antibodies against human 4-ibb (cd137)
AP2005003383A0 (en) Aminoheteroaryl compounds as protein kinase inhibitors.
MY163480A (en) Sclerostin binding agents
AU2003232194A1 (en) Fragrance containing emulsions
AU2003274652A8 (en) Compounds, compositions and methods for modulating fat metabolism
AU2003297305A1 (en) Coke drum bottom de-heading system
WO2005028678A3 (en) Methods and materials for identifying agents which modulate bone remodeling and agents identified thereby
WO2001096565A3 (en) Binding agents: chimeric ligand/receptor proteins
WO2003025137A3 (en) Sweet taste receptors
AU2003234198A8 (en) Novel genes, compositions, and methods for modulating the unfolded protein response
AU2003280594A1 (en) Fat composition for spread
WO2004011605A3 (en) Hybrid protein methods and compositions
WO2003066821A3 (en) Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
WO2006053315A3 (en) Methods and compositions for treating cellular proliferative diseases
WO2004045545A3 (en) Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression
WO2004070347A3 (en) Screening for modulators of fat storage
WO2004063339A3 (en) G-quadruplex binding assays and compounds therefor
WO2004098522A3 (en) Gemini vitamin d3 compounds and methods of use thereof
WO2007087053A3 (en) Bmp-7 variant compositions, methods and uses
WO2003087051A3 (en) Methods for identifying allosteric sites
WO2004094641A3 (en) A novel method of modulating bone-realted activity
TW200637830A (en) Erastin and erastin binding proteins, and uses thereof
AU2003289772A1 (en) Screening methods for membrane binding fungicides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2515347

Country of ref document: CA

Ref document number: 2006502228

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004707568

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004209335

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2004209335

Country of ref document: AU

Date of ref document: 20040203

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004209335

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004707568

Country of ref document: EP